Literature DB >> 20595688

One-hour postload plasma glucose levels are associated with kidney dysfunction.

Elena Succurro1, Franco Arturi, Marina Lugarà, Alessandro Grembiale, Teresa Vanessa Fiorentino, Vittoria Caruso, Francesco Andreozzi, Angela Sciacqua, Marta Letizia Hribal, Francesco Perticone, Giorgio Sesti.   

Abstract

BACKGROUND AND OBJECTIVES: A cutoff of 155 mg/dl for 1-hour postload plasma glucose (1hPG) during the oral glucose tolerance test (OGTT) is able to identify patients who are at high risk for type 2 diabetes and vascular atherosclerosis. We aimed to examine whether individuals with 1hPG ≥155 mg/dl are also at increased risk for chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Atherosclerosis risk factors, OGTT, and estimated GFR by Chronic Kidney Disease Epidemiology Collaboration equation were analyzed in 1075 white individuals without diabetes.
RESULTS: The area under the receiver operating characteristic curve for 1hPG was the highest (0.700) compared with the areas under the receiver operating characteristic curve of 0, 30-minute, and 2-hour glucose concentrations. Individuals with 1hPG ≥155 mg/dl had a worse cardiometabolic risk profile, exhibiting significantly higher body mass index, BP, triglycerides, and fasting insulin levels and lower HDL, IGF-1 levels, and insulin sensitivity, than individuals with 1hPG <155 mg/dl. Estimated GFR was significantly lower in individuals with 1hPG ≥155 mg/dl. In a logistic regression model adjusted for age and gender, individuals with 1hPG ≥155 mg/dl showed an increased risk for CKD compared with individuals with 1hPG <155 mg/dl. When the logistic regression analysis was restricted to individuals who had normal glucose tolerance, those with 1hPG ≥155 mg/dl showed a higher risk for CKD compared with individuals with 1hPG <155 mg/dl.
CONCLUSIONS: These data suggest that a cutoff point of 155 mg/dl for the 1hPG during OGTT may be helpful in the identification of individuals who are at increased risk for CKD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595688      PMCID: PMC3001771          DOI: 10.2215/CJN.03240410

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  29 in total

1.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

Authors:  E R DeLong; D M DeLong; D L Clarke-Pearson
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

2.  Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation.

Authors:  K C Leung; N Doyle; M Ballesteros; M J Waters; K K Ho
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

3.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

4.  Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia.

Authors:  In-Kyu Lee; Hye-Soon Kim; Jang-Ho Bae
Journal:  Int J Clin Pract Suppl       Date:  2002-07

5.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

Review 6.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.

Authors:  N Unwin; J Shaw; P Zimmet; K G M M Alberti
Journal:  Diabet Med       Date:  2002-09       Impact factor: 4.359

7.  Somatogenic receptors of rat liver: regulation by insulin.

Authors:  R C Baxter; J M Bryson; J R Turtle
Journal:  Endocrinology       Date:  1980-10       Impact factor: 4.736

8.  Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells.

Authors:  Simona I Chisalita; Hans J Arnqvist
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-01-13       Impact factor: 4.310

9.  The metabolic syndrome and chronic kidney disease in U.S. adults.

Authors:  Jing Chen; Paul Muntner; L Lee Hamm; Daniel W Jones; Vecihi Batuman; Vivian Fonseca; Paul K Whelton; Jiang He
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

10.  Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels.

Authors:  Gianluca Bardini; Ilaria Dicembrini; Barbara Cresci; Carlo Maria Rotella
Journal:  Diabetes Care       Date:  2009-11-16       Impact factor: 19.112

View more
  26 in total

1.  Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels.

Authors:  Jian-Bin Su; Tong Chen; Feng Xu; Xue-Qin Wang; Jin-Feng Chen; Gang Wu; Yan Jin; Xiao-Hua Wang
Journal:  Endocrine       Date:  2013-09-13       Impact factor: 3.633

2.  Reducing the prevalence of dysglycemia: is the time ripe to test the effectiveness of intervention in high-risk individuals with elevated 1 h post-load glucose levels?

Authors:  Michael Bergman; Ram Jagannathan; Martin Buysschaert; Jose Luis Medina; Mary Ann Sevick; Karin Katz; Brenda Dorcely; Jesse Roth; Angela Chetrit; Rachel Dankner
Journal:  Endocrine       Date:  2017-01-25       Impact factor: 3.633

3.  One-hour and two-hour postload plasma glucose concentrations are comparable predictors of type 2 diabetes mellitus in Southwestern Native Americans.

Authors:  Ethan Paddock; Maximilian G Hohenadel; Paolo Piaggi; Pavithra Vijayakumar; Robert L Hanson; William C Knowler; Jonathan Krakoff; Douglas C Chang
Journal:  Diabetologia       Date:  2017-06-29       Impact factor: 10.122

4.  Elevated 1-h post-load plasma glucose is associated with right ventricular morphofunctional parameters in hypertensive patients.

Authors:  Angela Sciacqua; Maria Perticone; Sofia Miceli; Angelina Pinto; Velia Cassano; Elena Succurro; Francesco Andreozzi; Marta Letizia Hribal; Giorgio Sesti; Francesco Perticone
Journal:  Endocrine       Date:  2019-02-21       Impact factor: 3.633

5.  Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance.

Authors:  Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Benedetto Caroleo; Sofia Miceli; Michele Andreucci; Anna Licata; Giorgio Sesti; Francesco Perticone
Journal:  Intern Emerg Med       Date:  2015-11-23       Impact factor: 3.397

6.  Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting.

Authors:  Ram Jagannathan; Mary Ann Sevick; Huilin Li; Dorothy Fink; Rachel Dankner; Angela Chetrit; Jesse Roth; Michael Bergman
Journal:  Endocrine       Date:  2015-09-29       Impact factor: 3.633

7.  Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: angiotensin-converting enzyme inhibitors.

Authors:  Eberhard Ritz
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04       Impact factor: 3.738

8.  Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension.

Authors:  Angela Sciacqua; Raffaele Maio; Sofia Miceli; Alessandra Pascale; Giuseppe Carullo; Nadia Grillo; Franco Arturi; Giorgio Sesti; Francesco Perticone
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet.

Authors:  Giorgio Sesti; Franco Folli; Lucia Perego; Marta Letizia Hribal; Antonio E Pontiroli
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

10.  Asymmetric dimethylarginine plasma levels and endothelial function in newly diagnosed type 2 diabetic patients.

Authors:  Angela Sciacqua; Nadia Grillo; Michele Quero; Giorgio Sesti; Francesco Perticone
Journal:  Int J Mol Sci       Date:  2012-10-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.